Research and development of drug delivery systems based on drug transporter and nano-formulation

In recent years,the continuous occurrence of multi-drug resistance in the clinic has made people pay more attention to the transporter.Changes in the expression and activity of transporters can cause corresponding changes in drug pharmacokinetics and pharmacodynamics.The drug-drug interactions(DDI)caused by transporters can seriously affect drug effectiveness and toxicity.In the development of pharmaceutical preparations,people have increasingly concerned about the effects and regulation of transporters in drug effects.To improve the targeting and physicochemical properties of drugs,the development of targeted agents is very rapid.Among them,novel nano-formulations are the best.With the continuous innovation and development of nano-formulation,its application has become more and more extensive.Nano-formulation has exerted certain advantages in the drug development based on transporters,and is also involved in the combination of targeted transporters.This review focuses on the application of novel nano-agents targeting transporters and the introduction of drug-transporter-based nano-formulations.

Development of a UHPLC-MS/MS method for the quantification of ilaprazole enantiomers in rat plasma and its pharmacokinetic application

In Korea and China,ilaprazole is a widely used proton pump inhibitor in the treatment of gastric ulcers.In this study,a specific and sensitive LC-MS/MS method has been developed and validated for the quantification of ilaprazole enantiomers in the rat plasma,using R-lansoprazole as the internal standard.The enantioseparation was achieved on a CHIRALPAK AS-RH column(4.6 mm×150 mm,i.d.5 mm),with a mobile phase composed of 10 m M ammonium acetate aqueous solution and acetonitrile(60:40,V/V),at a flow-rate of 0.5 m L/min.The method was validated over the concentration range of 0.5 e300 ng/m L for both,R-and S-ilaprazole.The lower limit of quantification was 0.5 ng/m L for both enantiomers.The relative standard deviation(RSD)of intra-and inter-day precision of R-ilaprazole and S-ilaprazole was less than 10.9%,and the relative error accuracy(RE)ranged fromà0.5%e2.0%.Finally,the method was successfully evaluated in rats in a stereoselective pharmacokinetic study of the ilaprazole racemate.

Upregulation of miR-489-3p and miR-630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting OCT2

Renal cell carcinoma(RCC) is one of the most common malignant tumors affecting the urogenital system, accounting for 90% of renal malignancies. Traditional chemotherapy options are often the front-line choice of regimen in the treatment of patients with RCC, but responses may be modest or limited due to resistance of the tumor to anticarcinogen. Downregulated expression of organic cation transporter OCT2 is a possible mechanism underlying oxaliplatin resistance in RCC treatment. In this study, we observed that mi R-489-3 p and mi R-630 suppress OCT2 expression by directly binding to the OCT2 30-UTR. Meanwhile, via 786-O-OCT2-mi RNAs stable expression cell models, we found that mi RNAs could repress the classic substrate 1-methyl-4-phenylpyridinium(MPP+), fluorogenic substrate N,N-dimethyl-4-(2-pyridin-4-ylethenyl) aniline(ASP+), and oxaliplatin uptake by OCT2 both in vitro and in xenografts. In 33 clinical samples, mi R-489-3 p and mi R-630 were significantly upregulated in RCC, negatively correlating with the OCT2 expression level compared to that in adjacent normal tissues, using tissue microarray analysis and q PCR validation. The increased binding of c-Myc to the promoter of pri-mi R-630, responsible for the upregulation of mi R-630 in RCC, was further evidenced by chromatin immunoprecipitation and dual-luciferase reporter assay. Overall, this study indicated that mi R-489-3 p and mi R-630 function as oncotherapy-obstructing micro RNAs by directly targeting OCT2 in RCC.

Three new shRNA expression vectors targeting the CYP3A4 coding sequence to inhibit its expression

RNA interference(RNAi)is useful for selective gene silencing.Cytochrome P4503A4(CYP3A4),which metabolizes approximately 50% of drugs in clinical use,plays an important role in drug metabolism.In this study,we aimed to develop a short hairpin RNA(shRNA)to modulate CYP3A4 expression.Three new shRNAs(S1,S2 and S3)were designed to target the coding sequence(CDS)of CYP3A4,cloned into a shRNA expression vector,and tested in different cells.The mixture of three shRNAs produced optimal reduction(55%)in CYP3A4 CDS-luciferase activity in both CHL and HEK293 cells.Endogenous CYP3A4 expression in HepG2 cells was decreased about 50%at both mRNA and protein level after transfection of the mixture of three shRNAs.In contrast,CYP3A5 gene expression was not altered by the shRNAs,supporting the selectivity of CYP3A4 shRNAs.In addition,HepG2 cells transfected with CYP3A4 shRNAs were less sensitive to Ginkgolic acids,whose toxic metabolites are produced by CYP3A4.These results demonstrate that vector-based shRNAs could modulate CYP3A4 expression in cells through their actions on CYP3A4 CDS,and CYP3A4 shRNAs may be utilized to define the role of CYP3A4 in drug metabolism and toxicity.